Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.60 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15194324 | 0.80 | MAPK1 (0.57) | MAPK1FGFR3KDRJAK3LRRK2 | |
| SCHEMBL2484874 | 0.79 | MAPK1 (0.56) | MAPK1JAK3CREBBP | |
| SCHEMBL1849841 | 0.76 | MAPK1 (0.80) | MAPK1JAK3CREBBP | |
| SCHEMBL15653387 | 0.76 | MAPK1 (0.75) | MAPK1JAK3CREBBP | |
| SCHEMBL15652768 | 0.76 | MAPK1 (1.00) | MAPK1JAK3CREBBP | |
| SCHEMBL19657749 | 0.75 | MAPK1 (0.64) | MAPK1JAK3LRRK2CREBBP | |
| SCHEMBL28906256 | 0.75 | MAP4K1 (0.63) | MAPK1MAPT | |
| SCHEMBL16932938 | 0.74 | MAPK1 (0.50) | MAPK1FGFR3KDRJAK3PDPK1 | |
| SCHEMBL16932939 | 0.74 | MAPK1 (0.50) | MAPK1FGFR3KDRJAK3PDPK1 | |
| SCHEMBL15651919 | 0.74 | MAPK1 (0.65) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635581-B1 | 7-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-8865715-B2 | Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines | MERCK PATENT GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865715-B2 | Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines | MERCK PATENT GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865715-B2 | Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines | MERCK PATENT GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| WO-2012059171-A1 | 7-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | PDK1, PDK2, PDK3 | MAPK1 182/4885FGFR3 1294/4885KDR 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.